Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Ionis Pharmaceuticals (IONS)

NASDAQ: IONS · Biotechnology · Carlsbad, CA

Our rating: Neutral

Call changed from Positive to Neutral at $28.01, moderate conviction, November 16, 2026.

Breaks if: For Neutral to become Positive: next full fiscal year revenue reaches at least $1.2B (roughly 27% growth from the reported $944M) while FCF burn narrows to below $200M — both conditions required, as growth without improving cash economics does not change the thesis. For Neutral to become Cautious: year-over-year revenue growth decelerates below 10% in the next reported annual figures, or FCF burn widens beyond $450M in the next full fiscal year.

Key figures

Market value$4.4B
Revenue, last 12 months$960M
Net income, last 12 months−$547M
Free cash flow, last 12 months−$616M
Price to earningsn/a
Free cash flow yield−13.9%
Dividend yield0.0%
Operating margin−58.8%
Return on equity−108.1%
Beta to the S&P 5000.63
Volatility, annualized49.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$243M54.9%$-0.66−$192M
June 30, 2026$268M−40.7%$-0.69$549M
March 31, 2026$246M87.0%$-0.56−$815M
December 31, 2025$203M−10.3%$-1.41−$159M
September 30, 2025$157M17.1%$-0.80−$137M
June 30, 2025$452M100.7%$0.70$139M
March 31, 2025$132M10.1%$-0.93−$163M
December 31, 2024$227M−30.2%$-0.66−$142M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

24 ledger entries and 34 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.